FDA clears second Alzheimer’s drug in ‘foundational spark’ for field – Endpoints News
US regulators approved Eisai and Biogen’s Alzheimer’s drug lecanemab, a landmark moment for the disease and a second chance for the companies after their drug Aduhelm was a commercial flop in the…